Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Large Cell Lung Carcinoma
Stage IB Non-Small Cell Lung Carcinoma
Stage IB Squamous Cell Lung Carcinoma
Stage IIA Non-Small Cell Lung Carcinoma
Stage IIA Squamous Cell Lung Carcinoma
Stage IIB Non-Small Cell Lung Carcinoma
Stage IIB Squamous Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIA Squamous Cell Lung Carcinoma
Other: Cytology Specimen Collection Procedure
Other: Laboratory Biomarker Analysis
|Official Title:||Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)|
- Central clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105, as measured by rate of accrual [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]
- Feasibility of research grade formalin-fixed, paraffin-embedded tissue collection for CCG analysis, as measured by adequate specimens collected per month [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]
- Agreement of local genotyping methods (direct sequencing of EGFR, ALK FISH) with central Clinical Laboratory Improvement Amendments genotyping [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]For each locally used assay, agreement will be defined as the proportion of patients deemed mutant (or wild-type) by local and central assessment divided by the number of evaluable patients, where an evaluable patient is one who has a local assessment result and has submitted tissue for central assessment. An agreement rate of 90% or higher between the local assay and the central assessment will be deemed acceptable.
- Disease free survival (DFS) rate for lung cancers which are wild-type for EGFR and ALK [ Time Frame: Time from resection to the earliest of documented disease recurrence confirmed by biopsy, development of a new lung cancer confirmed by biopsy, or death from any cause, assessed at 2 years ] [ Designated as safety issue: No ]Using genomics performed at CCG, DFS rate will be calculated for each genotype-defined population constituting greater than 1% of the study cohort.
- Proportions of patients who decline to enroll [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]Reasons behind why potentially eligible ALK-rearranged/EGFR mutant patients decline to enroll onto the adjuvant trials will be summarized. Concern with randomization, or not needing further therapy versus those who become otherwise ineligible due to recurrent disease or missing the enrollment window will be catalogued.
- Spectrum of new mutations identified at recurrence [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]Genomic analysis will be performed on tissue collected at time of recurrence and compared to baseline genomics. New mutations in key oncogenes and tumor suppressor genes (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha and phosphatase and tensin homolog, etc) will be quantified.
|Study Start Date:||August 2014|
|Estimated Primary Completion Date:||June 2021 (Final data collection date for primary outcome measure)|
Ancillary-Correlative (marker identification and sequencing)
Patients undergo collection of blood and tissue samples for EGFR and ALK testing via direct sequencing and FISH. Patients that have had surgery prior to pre-registration will submit samples from the previous surgery for testing.
Other: Cytology Specimen Collection Procedure
Undergo collection of blood and tissue
Other Name: Cytologic SamplingOther: Laboratory Biomarker Analysis
Undergo laboratory analysis via direct sequencing and FISH
I. To centrally test resected non-small cell lung cancer (NSCLC) for genetic mutations to facilitate accrual to randomized adjuvant studies.
II. To obtain clinically annotated tumor tissue and patient-matched non-malignant deoxyribonucleic acid (DNA) from peripheral blood, as well as detailed epidemiologic and clinical follow-up data, to allow clinically annotated advanced genomic analyses in concert with the National Cancer Institute (NCI) Center for Cancer Genomics (CCG).
I. To characterize the natural history of molecularly characterized NSCLC to allow subsequent development of targeted therapies against genotype-defined subpopulations in the adjuvant and recurrent settings.
II. To cross-validate local genotyping assays for epidermal growth factor receptor (EGFR) and anaplastic lymphoma receptor tyrosine kinase (ALK) with a central reference standard.
I. To study the genomic evolution of lung cancers by comparing genomic characteristics at resection and at recurrence.
II. To understand reasons behind lack of enrollment to adjuvant targeted therapy studies for potentially eligible patients.
Patients undergo collection of blood and tissue samples for EGFR, ALK, and programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1)/cytotoxic t-lymphocyte-associated protein 4 (CTLA-4) testing via direct sequencing, fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Patients that have had surgery prior to pre-registration will submit samples from the previous surgery for testing.
After completion of study, patients that are not enrolled on either A081105, E4512, or EA5142 are followed up every 6 months for 5 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02194738
Show 1087 Study Locations
|Principal Investigator:||Geoffrey Oxnard||Alliance for Clinical Trials in Oncology|